GT BIOPHARMA, INC.

Analyst Reco. GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-15 pm EDT			5-day change	1st Jan Change
3.05 ^USD	-4.48%		-1.61%	-60.13%

Mar. 26	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 01	GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EF Hutton Starts GT Biopharma at Hold With $2 Price Target	23-01-05	MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	22-09-13	MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	22-08-12	MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	21-06-24	MT
GT BIOPHARMA : HC Wainwright Starts GT Biopharma at Buy With $25 Price Target	21-05-24	MT
GT BIOPHARMA : B. Riley Starts GT Biopharma at Buy with $21 PT, Says Solid Tumor Indications Represent Source of Potential Upside	21-04-13	MT
GT BIOPHARMA : Roth Capital Starts GT Biopharma at Buy With $25 Price Target	21-03-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW